Last reviewed · How we verify
ASP3325
At a glance
| Generic name | ASP3325 |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan (PHASE1)
- A Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP3325 CI brief — competitive landscape report
- ASP3325 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI